Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

The AMPLITUDE-O trial evaluated the cardiovascular and renal outcomes of efpeglenatide, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, in patients with type 2 diabetes and high cardiovascular risk. The study involved 4,076 participants randomized to receive efpeglenatide (4 mg or 6 mg) or placebo. Over a median follow-up of 1.81 years, efpeglenatide significantly reduced the risk of major adverse cardiovascular events (MACE) by 27% (hazard ratio [HR] 0.73) and composite renal outcomes by 32% (HR 0.68) compared to placebo. Gastrointestinal side effects were more common with efpeglenatide, but no significant safety concerns were identified. The findings suggest efpeglenatide offers cardiovascular and renal benefits in high-risk patients with type 2 diabetes.

The AMPLITUDE-O trial evaluated the cardiovascular and renal outcomes of efpeglenatide, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, in patients with type 2 diabetes and high cardiovascular risk. The study involved 4,076 participants randomized to receive efpeglenatide (4 mg or 6 mg) or placebo. Over a median follow-up of 1.81 years, efpeglenatide significantly reduced the risk of major adverse cardiovascular events (MACE) by 27% (hazard ratio [HR] 0.73) and composite renal outcomes by 32% (HR 0.68) compared to placebo. Gastrointestinal side effects were more common with efpeglenatide, but no significant safety concerns were identified. The findings suggest efpeglenatide offers cardiovascular and renal benefits in high-risk patients with type 2 diabetes.